Cartesian Therapeutics, Inc. (RNAC) Free cash flow
- Free cash flow · 12 months (USD): Value $-78.61M; Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | $-78.61M | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. $-76.53M − $2.08M ≈ $-78.61M |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | (m) | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $-76.53M | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | 0.50× | Operating cash flow / net income. Period ending 2026-06-30. $-76.53M ÷ $-151.89M ≈ 0.50× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | -76.53M USD | Net Cash Provided by (Used in) Operating Activities · Net Cash Provided by (Used in) Operating Activities, Continuing Operations |
| Capital spending | 2.08M USD | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | -78.61M USD | Net Cash Provided by (Used in) Operating Activities · Net Cash Provided by (Used in) Operating Activities, Continuing Operations · Payments to Acquire Property, Plant, and Equipment |
| Revenue | 0.00 USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | -151.89M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $-78.61M | (m) | $-76.53M | $2.08M | (m) | $0.00 | (m) | $-151.89M | (m) | (m) | (m) | 0.50× |
| 2026-03-31 | $-77.37M | (m) | $-72.97M | $4.41M | (m) | $0.00 | (m) | $-151.77M | (m) | (m) | (m) | 0.48× |
| 2025-12-31 | $-79.39M | (m) | $-73.94M | $5.45M | (m) | $400.00K | (m) | $-130.30M | (m) | (m) | -19848.75% | 0.57× |
| 2025-09-30 | $-68.90M | (m) | $-63.23M | $5.67M | (m) | $-436.00K | (m) | $-47.98M | (m) | (m) | 15802.29% | 1.32× |
| 2025-06-30 | $-44.51M | (m) | $-33.94M | $10.57M | (m) | $-436.00K | (m) | $-36.26M | (m) | (m) | 10209.63% | 0.94× |
| 2025-03-31 | $-40.43M | (m) | $-30.86M | $9.57M | (m) | $32.84M | (m) | $-38.31M | (m) | (m) | -123.13% | 0.81× |
| 2024-12-31 | $-32.77M | (m) | $-23.67M | $9.09M | (m) | $38.27M | (m) | $-77.42M | (m) | (m) | -85.61% | 0.31× |
| 2024-09-30 | $-48.41M | (m) | $-39.96M | $8.45M | (m) | $47.38M | (m) | $-244.83M | (m) | (m) | -102.18% | 0.16× |
| 2024-06-30 | $-65.12M | (m) | $-62.86M | $2.25M | (m) | $53.93M | (m) | $-229.65M | (m) | (m) | -120.75% | 0.27× |
| 2024-03-31 | $-58.99M | (m) | $-58.31M | $678.00K | (m) | $25.91M | (m) | $-254.87M | (m) | (m) | -227.71% | 0.23× |
| 2023-12-31 | $-51.37M | (m) | $-51.16M | $206.00K | (m) | $26.00M | (m) | $-219.71M | (m) | (m) | -197.53% | 0.23× |
| 2023-09-30 | $-40.08M | (m) | $-39.72M | $353.00K | (m) | $34.53M | (m) | $-36.16M | (m) | (m) | -116.05% | 1.10× |
| 2023-06-30 | $-26.95M | (m) | $-26.16M | $789.00K | (m) | $48.69M | (m) | $-35.05M | (m) | (m) | -55.34% | 0.75× |
| 2023-03-31 | $-29.41M | (m) | $-28.53M | $876.00K | (m) | $82.72M | (m) | $-15.06M | (m) | (m) | -35.55% | 1.89× |
| 2022-12-31 | $-32.83M | (m) | $-31.63M | $1.20M | (m) | $110.78M | (m) | $35.38M | (m) | (m) | -29.64% | -0.89× |
| 2022-09-30 | $-52.51M | (m) | $-51.24M | $1.27M | (m) | $123.92M | (m) | $41.73M | (m) | (m) | -42.37% | -1.23× |
| 2022-06-30 | $-67.34M | (m) | $-66.34M | $996.00K | (m) | $127.64M | (m) | $31.72M | (m) | (m) | -52.76% | -2.09× |
| 2022-03-31 | $-61.63M | (m) | $-60.11M | $1.51M | (m) | $108.03M | (m) | $27.69M | (m) | (m) | -57.05% | -2.17× |
| 2021-12-31 | $-61.47M | (m) | $-60.38M | $1.08M | (m) | $85.08M | (m) | $-25.69M | (m) | (m) | -72.25% | 2.35× |
| 2021-09-30 | $-37.17M | (m) | $-36.17M | $997.00K | (m) | $67.09M | (m) | $-53.37M | (m) | (m) | -55.40% | 0.68× |
| 2021-06-30 | $39.09M | (m) | $40.21M | $1.12M | (m) | $47.31M | (m) | $-45.21M | (m) | (m) | 82.62% | -0.89× |
| 2021-03-31 | $33.74M | (m) | $34.45M | $705.00K | (m) | $27.65M | (m) | $-73.85M | (m) | (m) | 122.04% | -0.47× |
| 2020-12-31 | $34.07M | (m) | $34.88M | $815.00K | (m) | $16.60M | (m) | $-68.88M | (m) | (m) | 205.25% | -0.51× |
| 2020-09-30 | $28.59M | (m) | $29.25M | $662.00K | (m) | $11.30M | (m) | $-68.32M | (m) | (m) | 253.04% | -0.43× |
| 2020-06-30 | $-47.88M | (m) | $-47.50M | $376.00K | (m) | $6.65M | (m) | $-70.58M | (m) | (m) | -719.57% | 0.67× |
| 2020-03-31 | $-43.08M | (m) | $-42.89M | $182.00K | (m) | $6.67M | (m) | $-62.90M | (m) | (m) | -646.09% | 0.68× |
| 2019-12-31 | $-51.48M | (m) | $-51.44M | $47.00K | (m) | $6.68M | (m) | $-55.35M | (m) | (m) | -771.03% | 0.93× |
| 2019-09-30 | $-51.69M | (m) | $-51.31M | $378.00K | (m) | $926.00K | (m) | $-55.11M | (m) | (m) | -5581.53% | 0.93× |
| 2019-06-30 | $-56.65M | (m) | $-56.22M | $433.00K | (m) | $926.00K | (m) | $-59.12M | (m) | (m) | -6117.60% | 0.95× |
| 2019-03-31 | $-66.68M | (m) | $-65.99M | $692.00K | (m) | $913.00K | (m) | $-61.52M | (m) | (m) | -7303.83% | 1.07× |
| 2018-12-31 | $-60.05M | (m) | $-59.16M | $884.00K | (m) | $903.00K | (m) | $-65.34M | (m) | (m) | -6649.50% | 0.91× |
| 2018-09-30 | $-59.75M | (m) | $-59.09M | $665.00K | (m) | $17.00K | (m) | $-70.23M | (m) | (m) | -351470.59% | 0.84× |
| 2018-06-30 | $-59.22M | (m) | $-58.49M | $730.00K | (m) | $44.00K | (m) | $-68.90M | (m) | (m) | -134588.64% | 0.85× |
| 2018-03-31 | $-51.00M | (m) | $-50.13M | $867.00K | (m) | $70.00K | (m) | $-66.08M | (m) | (m) | -72852.86% | 0.76× |
| 2017-12-31 | $-52.77M | (m) | $-52.04M | $733.00K | (m) | $207.00K | (m) | $-65.32M | (m) | (m) | -25492.75% | 0.80× |
| 2017-09-30 | $-38.50M | (m) | $-37.81M | $692.00K | (m) | $3.12M | (m) | $-59.86M | (m) | (m) | -1234.01% | 0.63× |
| 2017-06-30 | $-28.68M | (m) | $-27.84M | $843.00K | (m) | $4.14M | (m) | $-52.91M | (m) | (m) | -692.56% | 0.53× |
| 2017-03-31 | $-25.34M | (m) | $-24.84M | $501.00K | (m) | $6.13M | (m) | $-43.87M | (m) | (m) | -413.19% | 0.57× |
| 2016-12-31 | $-20.27M | (m) | $-19.68M | $586.00K | (m) | $8.08M | (m) | $-36.21M | (m) | (m) | -250.76% | 0.54× |
| 2016-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | (m) | (m) | (m) | (m) | $7.07M | (m) | $-26.92M | (m) | (m) | (m) | (m) |
| 2015-12-31 | $-23.63M | (m) | $-22.46M | $1.16M | (m) | $6.01M | (m) | $-25.17M | (m) | (m) | -393.05% | 0.89× |
| 2015-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | $-12.91M | (m) | $-12.69M | $227.00K | (m) | $3.04M | (m) | $-12.88M | (m) | (m) | -424.77% | 0.98× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |